Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations

  • Stephen Mullin
    Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, United Kingdom
  • Laura Smith
    Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, United Kingdom
  • Katherine Lee
    Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, United Kingdom
  • Gayle D’Souza
    NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
  • Philip Woodgate
    NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
  • Josh Elflein
    NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
  • Jenny Hällqvist
    Translational Mass Spectrometry Research Group, University College London Institute of Child Health, London, United Kingdom
  • Marco Toffoli
    Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, United Kingdom
  • Adam Streeter
    Department of Medical Statistics, University of Plymouth School of Medicine, Plymouth, United Kingdom
  • Joanne Hosking
    Department of Medical Statistics, University of Plymouth School of Medicine, Plymouth, United Kingdom
  • Wendy E. Heywood
    Translational Mass Spectrometry Research Group, University College London Institute of Child Health, London, United Kingdom
  • Rajeshree Khengar
    NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
  • Philip Campbell
    Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, United Kingdom
  • Jason Hehir
    Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, United Kingdom
  • Sarah Cable
    Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, United Kingdom
  • Kevin Mills
    Translational Mass Spectrometry Research Group, University College London Institute of Child Health, London, United Kingdom
  • Henrik Zetterberg
    Department of Neurodegenerative Disease, University College London Institute of Neurology, London, United Kingdom
  • Patricia Limousin
    Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, United Kingdom
  • Vincenzo Libri
    NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
  • Tom Foltynie
    Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, United Kingdom
  • Anthony H. V. Schapira
    Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, United Kingdom

書誌事項

タイトル別名
  • A Nonrandomized, Noncontrolled Trial
公開日
2020-04-01
DOI
  • 10.1001/jamaneurol.2019.4611
公開者
American Medical Association (AMA)

この論文をさがす

収録刊行物

  • JAMA Neurology

    JAMA Neurology 77 (4), 427-, 2020-04-01

    American Medical Association (AMA)

被引用文献 (5)*注記

もっと見る

問題の指摘

ページトップへ